Literature DB >> 21449008

Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease.

Catherine L Gallagher1, Terrence R Oakes, Sterling C Johnson, Moo K Chung, James E Holden, Barbara B Bendlin, Donald G McLaren, Guofan Xu, Robert J Nickles, Robert Pyzalski, Onofre DeJesus, W Douglas Brown.   

Abstract

BACKGROUND: Rate of decline in 6-L-[(18)F]fluorodopa (FDOPA) uptake within the striatum has been reported as showing regional differences in Parkinson's disease (PD).
METHODS: We acquired longitudinal brain FDOPA positron emission tomography (PET) studies in 26 PD subjects and 11 controls over 4.5 years. We analyzed both spatially normalized voxel-wise maps of radiotracer influx (Kocc) and average Kocc values for six non-overlapping volumes of interest (VOIs) encompassing the striatum.
RESULTS: The voxel-wise analysis showed that in PD, FDOPA Kocc decline spanned the striatum but was greatest in the posterior putamen ipsilateral and anterior putamen contralateral to initial symptoms. The VOI approached showed that absolute rates of Kocc decline were significantly greater in PD than control subjects, but that the slope of decline did not differ between subregions. In PD, ratios of uptake between subregions did not change during the study with the exception of the ipsilateral putamen/caudate ratio. Decline rates were marginally greater during earlier time segments. Both male gender and advancing age were associated with lower baseline FDOPA uptake, but no difference in decline rates. VOI Kocc values were significantly correlated with disease duration, but only moderately correlated with clinical measures. DISCUSSION: We conclude that FDOPA uptake in subregions of the striatum is strongly correlated with disease duration and age, and declines approximately equally from symptom onset in PD. This implies that in idiopathic PD, relative preservation of uptake in the anterior striatum reflects a delay in pathologic involvement of nigrostriatal projections to this region.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21449008      PMCID: PMC3080432          DOI: 10.1002/mds.23503

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  31 in total

1.  Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex.

Authors:  V Kaasinen; E Nurmi; A Brück; O Eskola; J Bergman; O Solin; J O Rinne
Journal:  Brain       Date:  2001-06       Impact factor: 13.501

2.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.

Authors:  H Bernheimer; W Birkmayer; O Hornykiewicz; K Jellinger; F Seitelberger
Journal:  J Neurol Sci       Date:  1973-12       Impact factor: 3.181

3.  Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations.

Authors:  C S Patlak; R G Blasberg
Journal:  J Cereb Blood Flow Metab       Date:  1985-12       Impact factor: 6.200

4.  Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data.

Authors:  C S Patlak; R G Blasberg; J D Fenstermacher
Journal:  J Cereb Blood Flow Metab       Date:  1983-03       Impact factor: 6.200

5.  Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.

Authors:  E Nurmi; H M Ruottinen; J Bergman; M Haaparanta; O Solin; P Sonninen; J O Rinne
Journal:  Mov Disord       Date:  2001-07       Impact factor: 10.338

6.  Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET.

Authors:  Elina Nurmi; Jörgen Bergman; Olli Eskola; Olof Solin; Tero Vahlberg; Pirkko Sonninen; Juha O Rinne
Journal:  Synapse       Date:  2003-06-01       Impact factor: 2.562

7.  Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.

Authors:  Alan L Whone; Ray L Watts; A Jon Stoessl; Margaret Davis; Sven Reske; Claude Nahmias; Anthony E Lang; Olivier Rascol; Maria J Ribeiro; Philippe Remy; Werner H Poewe; Robert A Hauser; David J Brooks
Journal:  Ann Neurol       Date:  2003-07       Impact factor: 10.422

8.  Levodopa effect on [18F]fluorodopa influx to brain: normal volunteers and patients with Parkinson's disease.

Authors:  Y Kumakura; E H Danielsen; A Reilhac; A Gjedde; P Cumming
Journal:  Acta Neurol Scand       Date:  2004-09       Impact factor: 3.209

9.  Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography.

Authors:  E S Garnett; C Nahmias; G Firnau
Journal:  Can J Neurol Sci       Date:  1984-02       Impact factor: 2.104

10.  Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms.

Authors:  Vesna Sossi; Raúl de la Fuente-Fernández; James E Holden; Michael Schulzer; Thomas J Ruth; Jon Stoessl
Journal:  J Cereb Blood Flow Metab       Date:  2004-08       Impact factor: 6.200

View more
  11 in total

Review 1.  Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed?

Authors:  Sagar Kansara; Akash Trivedi; Sheng Chen; Joseph Jankovic; Weidong Le
Journal:  J Neural Transm (Vienna)       Date:  2012-06-26       Impact factor: 3.575

2.  18F-DOPA uptake parameters in glioma: effects of patients' characteristics and prior treatment history.

Authors:  Luciano Carideo; Giuseppe Minniti; Marcelo Mamede; Claudia Scaringi; Ivana Russo; Francesco Scopinaro; Francesco Cicone
Journal:  Br J Radiol       Date:  2018-01-19       Impact factor: 3.039

3.  [18F]FDOPA positron emission tomography in manganese-exposed workers.

Authors:  Susan R Criswell; Susan Searles Nielsen; Mark Warden; Joel S Perlmutter; Stephen M Moerlein; Hubert P Flores; John Huang; Lianne Sheppard; Noah Seixas; Harvey Checkoway; Brad A Racette
Journal:  Neurotoxicology       Date:  2017-07-08       Impact factor: 4.294

4.  Anterior cingulate dopamine turnover and behavior change in Parkinson's disease.

Authors:  Catherine L Gallagher; Brian Bell; Matthew Palotti; Jen Oh; Bradley T Christian; Ozioma Okonkwo; Jitka Sojkova; Laura Buyan-Dent; Robert J Nickles; Sandra J Harding; Charles K Stone; Sterling C Johnson; James E Holden
Journal:  Brain Imaging Behav       Date:  2015-12       Impact factor: 3.978

Review 5.  The role of neuroimaging in Parkinson's disease.

Authors:  Natasha S R Bidesi; Ida Vang Andersen; Albert D Windhorst; Vladimir Shalgunov; Matthias M Herth
Journal:  J Neurochem       Date:  2021-10-03       Impact factor: 5.546

6.  Onset pattern of nigrostriatal denervation in early Parkinson's disease.

Authors:  José A Pineda-Pardo; Álvaro Sánchez-Ferro; Mariana H G Monje; Nicola Pavese; José A Obeso
Journal:  Brain       Date:  2022-04-29       Impact factor: 15.255

7.  Comparison of Transcranial Sonography and [18 F]-Fluorodopa PET Imaging in GBA1 Mutation Carriers.

Authors:  Daniel P Eisenberg; Grisel Lopez; Michael D Gregory; Karen F Berman; Ellen Sidransky
Journal:  Mov Disord       Date:  2021-11-11       Impact factor: 9.698

8.  Physiological Whole-Brain Distribution of [18F]FDOPA Uptake Index in Relation to Age and Gender: Results from a Voxel-Based Semi-quantitative Analysis.

Authors:  Sinn-Rithy Toch; Sylvain Poussier; Emilien Micard; Marc Bertaux; Axel Van Der Gucht; Elodie Chevalier; Pierre-Yves Marie; Eric Guedj; Antoine Verger
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

9.  Resting state functional connectivity of the striatum in Parkinson's disease.

Authors:  Carl D Hacker; Joel S Perlmutter; Susan R Criswell; Beau M Ances; Abraham Z Snyder
Journal:  Brain       Date:  2012-11-28       Impact factor: 13.501

10.  Manganese neurotoxicity: new perspectives from behavioral, neuroimaging, and neuropathological studies in humans and non-human primates.

Authors:  Tomás R Guilarte
Journal:  Front Aging Neurosci       Date:  2013-06-24       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.